# US 2015/0105388 A1 · Carboxamide-substituted heteroaryl-pyrazoles and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105388 A1
- Document ID: US20150105388A1
- Status: Published application
- Kind: A1
- Application number: 14/361,126
- Filed: 2012-11-29
- Published: 2015-04-16
- Earliest claimed: 2011-11-29
- Assignees: AiCuris GmbH & Co. KG
- Applicants: AiCuris GmbH & Co. KG
- Inventors: Steffen Wildum; Burkhard Klenke; Astrid Wendt
- Web page: https://patentgrep.com/patent/US20150105388A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to new carboxamide-substituted heteroaryl-pyrazoles, method for their production, their use for the treatment and/or prophylaxis of diseases, as well as their use for the production of pharmaceutical agents for the treatment and/or prophylaxis of diseases, in particular retroviral diseases, in humans and/or animals.

## Claims

### Claim at position 1

-19. (canceled)

### Claim 20

Compound of Formula
in which
R1 stands for phenyl or pyridyl,
whereby phenyl is substituted with 1 to 3, preferably 2, substituents, whereby the substituents are selected independently of one another from the group that consists of halogen, hydroxy, amino, cyano, nitro, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, (C1-C4)-alkylamino and (C1-C4)-alkoxy,
in which
alkyl, cycloalkyl, alkylamino and alkoxy, for their part, can be substituted in one to three places, in the same way or differently, with radicals selected from the series halogen, cyano, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl, and 4- to 7-membered heterocyclyl,
and
whereby pyridyl can be substituted with 1 or 2 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, hydroxy, amino, cyano, nitro, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, and (C1-C4)-alkoxy, and whereby the nitrogen atom of the pyridyl can form an N-oxide,
in which
alkyl, cycloalkyl and alkoxy, for their part, can be substituted in one to three places, in the same way or differently, with radicals selected from the series halogen, cyano, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl, and 4- to 7-membered heterocyclyl,
R2 stands for phenyl or pyridyl,
whereby phenyl is substituted with 1 to 3, preferably 2, substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, hydroxy, amino, cyano, nitro, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, (C1-C4)-alkylamino, and (C1-C4)-alkoxy,
in which
alkyl, cycloalkyl, alkylamino, and alkoxy, for their part, can be substituted in one to three places, in the same way or differently, with radicals selected from the series halogen, cyano, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl, and 4- to 7-membered heterocyclyl,
and
whereby pyridyl can be substituted with 1 or 2 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, hydroxy, amino, cyano, nitro, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, and (C1-C4)-alkoxy, and whereby the nitrogen atom of pyridyl can form an N-oxide
in which
alkyl, cycloalkyl, and alkoxy, for their part, can be substituted in one to three places, in the same way or differently, with radicals selected from the series halogen, cyano, hydroxy, (C1-C4)-alkoxy, amino, mono-(C1-C4)-alkylamino, di-(C1-C4)-alkylamino, (C3-C7)-cycloalkyl, and 4- to 7-membered heterocyclyl, and
A stands for a 5- to 8-membered heterocyclic compound bonded via nitrogen,
whereby the heterocyclic compound can be substituted with 1 to 3 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, hydroxy, hydroxymethyl, formyl, amino, oxo, trifluoromethyl, trifluoromethoxy, (C1-C4)-alkyl, (C1-C4)-alkoxy, and (C1-C4)-alkoxycarbonyl,
whereby R2 stands for pyridyl, when R1 stands for phenyl,
whereby R2 stands for phenyl, when R1 stands for pyridyl, and
whereby when R1 stands for 3-pyridyl, the latter cannot be substituted with unsubstituted alkoxy,
and their salts, their solvates, and the solvates of their salts,
except for the following compounds

### Claim 21 (depends on 20)

Compound according to claim 20, characterized in that
R1 stands for phenyl or pyridyl,
whereby phenyl is substituted with 1 or 2 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, amino, methyl, and trifluoromethyl, and
whereby pyridyl can be substituted with 1 or 2 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, amino, methyl, and trifluoromethyl, and whereby the nitrogen atom of the pyridyl can form an N-oxide,
R2 stands for phenyl or pyridyl,
whereby phenyl is substituted with 1 or 2 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, cyano, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, and (C1-C4)-alkoxy,
in which
alkyl, cycloalkyl, and alkoxy, for their part, can be substituted with 1 to 3 fluorine atoms, and
whereby pyridyl can be substituted with 1 or 2 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, cyano, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, and (C1-C4)-alkoxy, and whereby the nitrogen atom of pyridyl can form an N-oxide, in which
alkyl, cycloalkyl, and alkoxy, for their part, can be substituted with 1 to 3 fluorine atoms, and
A stands for Imidazolidine-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1,3-thiazolidin-3-yl, piperidin-1-yl, piperazin-1-yl or 1,4-oxazepan-4-yl,
whereby Imidazolidine-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1,3-thiazolidin-3-yl, piperidin-1-yl, piperazin-1-yl or 1,4-oxazepan-4-yl can be substituted with 1 to 3 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, hydroxy, hydroxymethyl, formyl, amino, oxo, trifluoromethyl, trifluoromethoxy, (C1-C4)-alkyl, (C1-C4)-alkoxy, and (C1-C4)-alkoxycarbonyl,
whereby R2 stands for pyridyl, when R1 stands for phenyl,
whereby R2 stands for phenyl, when R1 stands for pyridyl,
and their salts, their solvates, and the solvates of their salts.

### Claim 22 (depends on 20)

Compound according to claim 20, wherein
R1 stands for pyridyl,
whereby pyridyl can be substituted with 1 or 2 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, amino, methyl, and trifluoromethyl, and whereby the nitrogen atom of pyridyl can form an N-oxide,
R2 stands for phenyl,
whereby phenyl is substituted with 1 to 2 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, cyano, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, and (C1-C4)-alkoxy,
in which
alkyl, cycloalkyl, and alkoxy, for their part, can be substituted with 1 to 3 fluorine atoms, and
A stands forImidazolidine-1-yl, morpholin-4-yl, 1,3-thiazolidin-3-yl or piperazin-1-yl,
whereby Imidazolidine-1-yl, morpholin-4-yl, 1,3-thiazolidin-3-yl or piperazin-1-yl can be substituted with 1 to 3 substituents, whereby the substituents, independently of one another, are selected from the group that consists of hydroxy, amino, oxo, (C1-C4)-alkyl, and (C1-C4)-alkoxy, and their salts, their solvates, and the solvates of their salts.

### Claim 23 (depends on 20)

Compound according to claim 20, wherein
R1 stands for 3-pyridyl or 4-pyridyl,
whereby pyridyl can be substituted with a halogen substituent,
R2 stands for phenyl,
whereby phenyl is substituted with 1 or 2 substituents, whereby the substituents, independently of one another, are selected from the group that consists of halogen, trifluoroalkoxy, and difluoroalkoxy, A stands forImidazolidine-1-yl, morpholin-4-yl, 1,3-thiazolidin-3-yl or piperazin-1-yl,
whereby Imidazolidine-1-yl, morpholin-4-yl, 1,3-thiazolidin-3-yl or piperazin-1-yl can be substituted with 1 to 3 substituents, whereby the substituents, independently of one another, are selected from the group that consists of oxo and (C1-C4)-alkyl,
and their salts, their solvates, and the solvates of their salts.

### Claim 24 (depends on 20)

Compound according to claim 20, wherein it corresponds to Formula
in which
R3 stands for hydrogen, halogen, amino, trifluoromethyl or (C1-C4)-alkyl,
R4 stands for hydrogen, halogen, (C1-C4)-alkyl or (C1-C4)-alkoxy,
in which alkyl and alkoxy can be substituted with 1 to 3 fluorine atoms, and
R5 stands for hydrogen, halogen, cyano, (C1-C4)-alkyl, (C3-C6)-cycloalkyl or (C1-C4)-alkoxy,
whereby R4 and R5 cannot be hydrogen at the same time, and their salts, their solvates, and the solvates of their salts.

### Claim 25 (depends on 24)

Compound according to claim 24, wherein
R3 stands for hydrogen or methyl,
R4 stands for fluorine, difluoromethoxy or trifluoromethoxy, and
R5 stands for fluorine, chlorine, bromine, or methoxy,
and their salts, their solvates, and the solvates of their salts.

### Claim 26 (depends on 20)

Compound according to claim 20, wherein it corresponds to Formula
in which
R6 stands for hydrogen, halogen, trifluoromethyl, (C1-C4)-alkyl or (C1-C4)-alkoxy,
R7 stands for hydrogen, halogen, (C1-C4)-alkyl or (C1-C4)-alkoxy, in which alkyl and alkoxy can be substituted with 1 to 3 fluorine atoms, and
R8 stands for hydrogen, halogen, cyano, (C1-C4)-alkyl, (C3-C6)-cycloalkyl or (C1-C4)-alkoxy,
whereby R7 and R8 cannot be hydrogen at the same time,
and their salts, their solvates, and the solvates of their salts.

### Claim 27 (depends on 26)

Compound according to claim 26, wherein
R6 stands for chlorine, trifluoromethyl, methyl, or methoxy,
R7 stands for fluorine, methoxy, difluoromethoxy, or trifluoromethoxy, and
R8 stands for fluorine, chlorine, bromine, or methoxy,
and their salts, their solvates, and the solvates of their salts.

### Claim 28 (depends on 20)

Compound according to claim 20, wherein it corresponds to Formula
in which
R9 stands for hydrogen, halogen, cyano, (C1-C4)-alkyl or (C1-C4)-alkoxy, in which alkyl and alkoxy can be substituted with 1 to 3 fluorine atoms,
R10 stands for hydrogen, halogen, trifluoromethyl, (C1-C4)-alkyl or (C1-C4)-alkoxy,
R11 stands for hydrogen, halogen, cyano, (C1-C4)-alkyl or (C1-C4)-alkoxy, in which alkyl and alkoxy can be substituted with 1 to 3 fluorine atoms, and
R12 stands for hydrogen or halogen,
whereby R9 and R10 cannot be hydrogen at the same time,
and their salts, their solvates, and the solvates of their salts.

### Claim 29 (depends on 20)

Compound according to claim 20, wherein it corresponds to Formula
in which
R13 stands for hydrogen, halogen, cyano, (C1-C4)-alkyl or (C1-C4)-alkoxy, in which alkyl and alkoxy can be substituted with 1 to 3 fluorine atoms,
R14 stands for hydrogen, halogen, trifluoromethyl, (C1-C4)-alkyl or (C1-C4)-alkoxy, and
R15 stands for hydrogen, halogen, cyano, (C1-C4)-alkyl or (C1-C4)-alkoxy, in which alkyl and alkoxy can be substituted with 1 to 3 fluorine atoms,
whereby R13 and R14 cannot be hydrogen at the same time, and their salts, their solvates, and the solvates of their salts.

### Claim 30 (depends on 1, 20)

Method for the production of a compound of Formula (I) according to claim 20, whereby a compound of Formula
in which
R1 and R2 have the above-indicated meaning, is reacted with a 5- to 8-membered heterocyclic compound as defined in claim 1 for A or a salt thereof.

### Claim 31 (depends on 20)

Compound according to claim 20 for treatment and/or prophylaxis of diseases.

### Claim 32 (depends on 20)

Compound according to claim 20 for use in a method for treatment and/or prophylaxis of infections with retroviruses, in particular with the HI virus.

### Claim 33 (depends on 20)

Use of a compound according to claim 20 for the production of a pharmaceutical agent for treatment and/or prophylaxis of diseases.

### Claim 34 (depends on 20)

Use of a compound according to claim 20 for the production of a pharmaceutical agent for treatment and/or prophylaxis of infections with retroviruses, in particular with the HI virus.

### Claim 35 (depends on 20)

Pharmaceutical agent, which contains at least one compound according to claim 20 in combination with at least one additional active ingredient.

### Claim 36 (depends on 20)

Pharmaceutical agent, which contains at least one compound according to claim 20 in combination with at least one inert, non-toxic, pharmaceutically suitable adjuvant.

### Claim 37 (depends on 35)

Pharmaceutical agent according to claim 35 for use in a method for treatment and/or prophylaxis of infections with retroviruses, in particular with the HI virus.

### Claim 38 (depends on 20)

Method for combating viral diseases in humans and animals, which features the administration of an antivirally effective amount of at least one compound according to claim 20 to a human or an animal who requires the latter.

### Claim 39 (depends on 38)

The method of claim 38, wherein the viral disease is from a retrovirus.
